Tuesday, 27 August 2024 5 Min Read
Frost & Sullivan Awards Avance Clinical for Global Biotech CRO Excellence, Highlighting Agility, Responsiveness, Customer Value, and Proven Ability to Expedite Quality Clinical Programs
Avance Clinical streamlines its biotech clients' clinical trial operations, workflows, and data management, optimizing study efficiencies, minimizing costs, and accelerating trial timelines.
SAN ANTONIO, Aug. 27, 2024 -- Frost & Sullivan recently assessed the biotech contract research organization (CRO) industry and, based on its results, recognizes Avance Clinical with the 2024 Global Customer Value Leadership Award. The company is a leading CRO facilitating top-tier clinical trials with globally recognized data for biotech firms worldwide. With an exclusive focus on the biotech sector, the company leverages over 30 years of deep clinical research experience across more than 250 therapeutic indications to provide customized services catering to biotech R&D's dynamic needs. Overall, the company's world-class team, exceeding 330 clinical and regulatory specialists, delivers high-quality clinical trials in Australia, New Zealand, Asia, Europe, and North America for international biotechs. As a full-service CRO, it builds on its extensive expertise across various modalities (ranging from small molecules to advanced cell therapies) to offer sophisticated solutions covering the entire spectrum of drug development, from preclinical stages through to Phase II/ III studies.
